Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 67; no. 5; p. 487
• Main Authors: Spreen, William, Williams, Peter, Margolis, David, Ford, Susan L, Crauwels, Herta, Lou, Yu, Gould, Elizabeth, Stevens, Marita, Piscitelli, Stephen
• Format: Journal Article
• Language: English
• Published: United States 15.12.2014
• Subjects: Adolescent; Adult; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - adverse effects; Delayed-Action Preparations - pharmacokinetics; Drug Therapy, Combination - adverse effects; Drug Therapy, Combination - methods; Female; Humans; Injections, Intramuscular; Injections, Subcutaneous; Male; Middle Aged; Nitriles - administration & dosage; Nitriles - adverse effects; Nitriles - pharmacokinetics; Pyridones - administration & dosage; Pyridones - adverse effects; Pyridones - pharmacokinetics; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Rilpivirine; Young Adult

Pharmacokinetics, safety, and tolerability of GSK1265744 (744) and rilpivirine (RPV) (TMC278) were assessed after repeat dosing of long-acting (LA) injectable formulations in healthy subjects. Subjects received a 14-day lead-in of oral 744 (30 mg/d) to assess safety and tolerability before injectabl...